This document discusses three arboviral diseases: Dengue, Chikungunya, and Kyasanur Forest Disease (KFD). Dengue and Chikungunya are transmitted by Aedes mosquitoes and cause acute febrile illness with joint pain. KFD is transmitted by ticks and found only in southern India, where it causes hemorrhagic fever with a 5-10% fatality rate. The document covers the clinical presentation, diagnosis, treatment and prevention of these diseases, emphasizing the importance of mosquito control and community cooperation to reduce transmission.
this presentation deals mainly with dengue as there has been multiple outbreaks in 2015 and etiological factors involved, current scenario in India, preventive and control measures for dengue, recent strains of dengue and recent vaccine trials of dengue vaccine.
this presentation deals mainly with dengue as there has been multiple outbreaks in 2015 and etiological factors involved, current scenario in India, preventive and control measures for dengue, recent strains of dengue and recent vaccine trials of dengue vaccine.
Dr. Sachin Verma is a young, diligent and dynamic physician. He did his graduation from IGMC Shimla and MD in Internal Medicine from GSVM Medical College Kanpur. Then he did his Fellowship in Intensive Care Medicine (FICM) from Apollo Hospital Delhi. He has done fellowship in infectious diseases by Infectious Disease Society of America (IDSA). He has also done FCCS course and is certified Advance Cardiac Life support (ACLS) and Basic Life Support (BLS) provider by American Heart Association. He has also done a course in Cardiology by American College of Cardiology and a course in Diabetology by International Diabetes Centre. He specializes in the management of Infections, Multiorgan Dysfunctions and Critically ill patients and has many publications and presentations in various national conferences under his belt. He is currently working in NABH Approved Ivy super-specialty Hospital Mohali as Consultant Intensivists and Physician.
Introduction
Some Recent Dengue Out breaks
Clinical manifestations of dengue
Problem statement
Epidemiological determinants
Transmission of disease
Clinical and Laboratory diagnosis
WHO classification and Grading of severity of dengue infection.
Guidelines for treatment:
Management of DHF Grade I, II, III and IV.
Indications for red cell and platelet transfusion.
Global and National strategies.
Conclusion &References.
Now a days.All the World is facing a serious problem..Dengue
so i make a presentation on dengue to prevent and aware from dengue...and if you have dengue faver then which types of treatment you use for your Health.
My Presentation in College.
Hope its useful for you rather than sleeping in my desktop.
Sorry if there is any mistakes.
The presentation is about Dengue fever. First starting with the basic information like Introduction , Epidemiology ,Vector , Viral Morphology ,Mode of Transmission. Then little bit on Pathogenesis and Immune Response. Extra focus given to the Clinical Manifestations, symptoms and Lab Diagnosis with few simplified case studies. Control and prevention and treatment also included.
Dr. Sachin Verma is a young, diligent and dynamic physician. He did his graduation from IGMC Shimla and MD in Internal Medicine from GSVM Medical College Kanpur. Then he did his Fellowship in Intensive Care Medicine (FICM) from Apollo Hospital Delhi. He has done fellowship in infectious diseases by Infectious Disease Society of America (IDSA). He has also done FCCS course and is certified Advance Cardiac Life support (ACLS) and Basic Life Support (BLS) provider by American Heart Association. He has also done a course in Cardiology by American College of Cardiology and a course in Diabetology by International Diabetes Centre. He specializes in the management of Infections, Multiorgan Dysfunctions and Critically ill patients and has many publications and presentations in various national conferences under his belt. He is currently working in NABH Approved Ivy super-specialty Hospital Mohali as Consultant Intensivists and Physician.
Introduction
Some Recent Dengue Out breaks
Clinical manifestations of dengue
Problem statement
Epidemiological determinants
Transmission of disease
Clinical and Laboratory diagnosis
WHO classification and Grading of severity of dengue infection.
Guidelines for treatment:
Management of DHF Grade I, II, III and IV.
Indications for red cell and platelet transfusion.
Global and National strategies.
Conclusion &References.
Now a days.All the World is facing a serious problem..Dengue
so i make a presentation on dengue to prevent and aware from dengue...and if you have dengue faver then which types of treatment you use for your Health.
My Presentation in College.
Hope its useful for you rather than sleeping in my desktop.
Sorry if there is any mistakes.
The presentation is about Dengue fever. First starting with the basic information like Introduction , Epidemiology ,Vector , Viral Morphology ,Mode of Transmission. Then little bit on Pathogenesis and Immune Response. Extra focus given to the Clinical Manifestations, symptoms and Lab Diagnosis with few simplified case studies. Control and prevention and treatment also included.
This webinar is organized by MyICID and Institute for Clinical Research (ICR), NIH, Ministry of Health in conjunction with Neglected Tropical Disease Day 2022. The purpose of this webinar is to refresh and update our knowledge on Dengue fever, which has been overshadowed by COVID-19 since the beginning of the pandemic.
Presenter: Dr Ong Hang Cheng, Infectious Disease Physician at University Malaya Medical Center
#dengue #WorldNTDDay #BeatNTDs #BestScienceforAll
Japanese encephalitis (JE) is an infection of the brain caused by the Japanese encephalitis virus (JEV). While most infections result in little or no symptoms, occasional inflammation of the brain occurs. In these cases, symptoms may include headache, vomiting, fever, confusion and seizures. This occurs about 5 to 15 days after infection.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
1. 1. DENGUE
2. CHIKUNGUNYA
3. KYASANUR FOREST DISEASE (KFD)
1
Dr. Sushrit A. Neelopant
Assistant Professor,
Department of Community Medicine
RIMS, Raichur
6. Problem statement-World
• 2.5 Bil.- at risk - Tropical & Sub Tropical regions
• 90% of affected – Children <5 years
• 2.5% of – affected - die.
• Pandemic in 1998: 1.2 million cases & 15,000 deaths
Annually:
5 crore infections,
5 lakh cases,
12 thousand deaths.
6
7. • Endemic - >100 countries-
– Africa, America, Eastern Mediterranean, SEAR,
Western Pacific.
Division of SEAR - based on endemicity:
• Category A: (Bangladesh, India, Indonesia, Maldives,
Myanmar, Sri Lanka & Thailand)
• Category B: Bhutan, Nepal; Endemicity uncertain.
• Category C: DPR Korea ; No Endemicity.
7
10. India
• Endemic in 31 states/UT.
• An emerging public health problem with cyclical
epidemics.
Epidemics Timeline:
• 1956: 1st epidemic, Vellore, Tamil Nadu.
• 1996: Delhi-10,252 cases, 423 deaths.
• 1997: Maharashtra
• 2003: 12,750 cases, 217 deaths all over country.
• 2011: 18,059 cases, 119 deaths.
Case Fatality rate: 0.65%
• Serotypes: DENV-1,2,3,4.
• Dengue is now the MCC of fever in India Malaria.
10
13. AGENT FACTORS
Agent & Vector
Dengue transmission
• It has 4 sero types & many sub types
• Aedes aegypti - most important
• Virus multiplies in the mosquito
• Mosquito develops life long non-cytocidal infection
13
14. Dengue vectors
Aedes aegypti:
• The most important vector in Africa, America & Asia.
• Mosquito prefers peri domestic settings
• Prefer to bite during day
• Aedes aegypti has a limited flying ability-100m
• Aedes albopictus is another vector
14
18. Clinical source
• Infection may be asymptomatic, atypical, classical or
can evolve to hemorrhagic syndrome with or without
shock
18
19. Classical dengue fever
• Sudden on onset
• Fever, headache, lymphadenopathy…
• No splenomegaly
• Marked muscle pain (Break bone fever)
• Fever - biphasic
• Rashes appear on the 3rd–5th day
19
20. Complicated dengue
• Dengue hemorrhagic fever (DHF)
• Dengue shock syndrome (DSS)
-Dramatic and mortality high
-Occurs mainly in children
-Development of neutralizing antibodies
20
21. DHF
• Fever
• Hemorrhagic complications ( + tourniquet test)
• Thrombocytopenia < 100000/ µl
• Signs of plasma loss
• Severity of the condition (DHF/DSS) can be given by
clinical score
21
23. Treatment
• Symptomatic
• Paracetamol, no aspirin (risk of bleeding)
• Hemorrhagic dengue: IV infusion, fluid balance,
blood transfusion
• Platelets transfusion
• Steroids can be used but not effective
24
24. Control & prevention
• Mosquito control
-vectors of DF & DHF breeding places controlled by
individual and community action
-anti adult & anti larval measures
• Vaccine: an experimental tetravalent vaccine
• Other measures: Mosquito nets & repellents
25
26. Introduction
• Chikungunya
– Transmission documented in 37 countries
• Primarily found in Africa and Asia
• 1.4 million cases reported in 2006
– Travel-associated cases documented in U.S.
• 109 cases since 1995
– Similarities with dengue
• Same vectors
• Humans can become reservoirs when infected
27
27. Chikungunya
• Viral illness
• Spread by mosquitoes
• Resembles Dengue fever
• Severe persistent joint pain [arthritis]
• Fever
• Rash
• Rarely life threatening
• Morbidity & economic loss
28.
29. Epidemiology
• India – 1824 [ Fever, rash & Arthritis ]
• Tanzania – 1952-1953 - First isolated
• Major epidemics – Cyclical
• Inter-epidemic period – 7-8 yrs[20yrs also]
30. INDIA
• Till Oct 2006 – 151 districts of 8 states/provinces
• AP, Andaman & Nicobar Islands, Tamil Nadu,
Karnataka, Maharashtra, Gujarat, Madhya Pradesh,
Kerala & Delhi.
• India total – 1.25 million cases
• Karnataka – 752245
• Maharashtra - 258998
• Attack rates – 45 %
32
31. Epidemiology:
• 1952-53: Virus isolated from human serum and
mosquitoes first time during an epidemic in Tanzania.
• 2004-06: An outbreak originating on the coast of
Kenya spread to several Indian Ocean islands and
Asia, causing millions of disease cases.
• 2007: Concern for the spread of CHIKV peaked, when
the virus was found to be spreading
autochthonously (human-to-mosquito-to-human) in
northern Italy.
33
34. Agent Factor
• Chikungunya is an Alphavirus of the family
Togaviridae.
• It is composed of an enveloped, single-strand,
positive sense RNA genome.
36
39. Chikungunya : The clinical picture
• The majority (72-97%)
of persons infected will
become symptomatic.
• Incubation Period: 3-7
days (1-12 days)
• Period of
Communicability : 3-10
days
43. Diagnosis
Three main types of
laboratory tests
• Virus isolation: Within the
first 3 days of illness.
• RT-PCR: Day 1-8, after onset
of illness.
• Serological assays for
IgM/IgG: 4 days after illness
and beyond.
National Center for Emerging and Zoonotic Infectious Diseases Division of Vector-Borne Diseases
44.
45. Virus Isolation
• Most definitive
• Sample – 2-5 ml Whole blood
• Time – 1st wk of illness
• Collection – Heparinized tube
• Transport – In Ice
• CHIK virus – Cytopathic effects in cell line – BHK-
21,HeLa & Vero Cells.
• Confirmed – CHIK specific Antiserum
• Results – 1-2 wks
• BSL-3 Labs – Reduces risk of viral transmission
46. RT - PCR
• Primer pairs amplifying specific components of 3
structural gene regions
- Capsid ( C )
- Envelope E2
- Part of Envelope E1
Results – 1-2 days
Specimen – Heparinized whole blood
47. Serological diagnosis
• Specimen – 10-15 ml whole blood sera
• Acute phase serum - Immediately
• Convalescent phase serum – 10-14 days after disease
onset
• Transported – At 4 degrees & not frozen
[immediately]
- If sera – Shipped frozen
48. Serological diagnosis
• Acute phase – 4 fold increase in Ab than
Convalescent phase
• Demonstrate IgM Ab specific for CHIK virus
- MAC-ELISA [IgM Ab Capture ELISA]
- Results – 2-3 days
- Cross reactions – O’nyong-nyong & Semliki Forest
- Confirmation – Neutralization tests & HIA
49. Existing Laboratory Network for Diagnosing
Chikungunya
Country Serological Test PCR
India National Institute of
Virology, Pune
National Institute of
Virology, Pune
Indonesia NIHRD, NAMRU-2, NIHRD ,NAMRU-2
Myanmar Department of Medical
Research
NA
Sri Lanka Medical Research
Institute
Medical Research
Institute
Thailand NIH, Bangkok, AFRIMS NIH, Bangkok, AFRIMS
50. Differential Diagnosis
• Diseases should be considered based upon
epidemiological features such as place of residence,
travel history and exposure.
• Dengue fever
• Leptospirosis
• Post-infection arthritis
• JRA
51. Management
- Not life threatening
- Symptomatic – Pain & Fever
- Rest
- Convalescence – 1 yr or more
- Persistent joint pain – Analgesic
- Long-term anti-inflammatory therapy
53
52. Treatment
Treatment: No specific antiviral drug
Acute Disease:
• Rest & Fluids
• NSAIDs (to relieve arthritic component)
Severe joint pains unresponsive to NSAIDs:
• Narcotics (e.g., morphine)
• Short-term corticosteroids
Subacute & Chronic Disease:
• Long-term anti-inflammatory therapy
• Intra-articular corticosteroids or topical NSAID
• Graduated physiotherapy
53. Prevention & Control
• No vaccine
• Prevention – Avoid Mosquito bites & Elimination of
breeding sites
55
54. • Full sleeve clothes & long dresses
• Mosquito coils, Repellents & Vapour mats
• Mosquito Nets – Babies, Old people.
• Nets & Curtains Treated with Permethrin
56
55. Prevent Mosquito breeding
• Manmade containers – Discarded tires,Flower
pots,old oil drums,animal water troughs,water
storage vessels,plastic food containers
• Eliminated by
- Draining from coolers,tanks,barrels,drums & buckets
- Emptying coolers when not in use
- Cooperating with public health authorities
56. Role of Public health authorities
• National programme – Strengthened & Efficiently
implemented
• Legislations – Enforced
• Communities – Active cooperation
58. • Introduction
• History
• Problem statement
• Epidemiological determinants
• Clinical features
• Diagnosis & Treatment
• Prevention & control
60
59. Introduction
• Febrile disease associated with hemorrhages
• Caused by Flavi virus of Togaviridae family.
• Transmitted to man by infected hard tick bite.
• Case fatality: 5-10%
61
60. History
• First isolated in 1957 in Kyasanur forest area.
• Sagar-Sorab taluk, Shimoga district, Karnataka
• Monkeys and local village population effected
• First called as monkey disease
• Later named as Kyasanur forest disease (KFD)
• Virus isolated at NIVRC, Pune
62
61. Problem statement
• Restricted to Shimoga, North Kannada, South
Kannada & Chickamalagalur districts.
• Area coverage- 6000 sq.km
• 1983 -84 largest outbreak with 2167 cases & 69
deaths
• 2001 February: Chickamagalur district
• Deaths of monkeys considered as heralders of
disease
63
64. Chikungunya & Dengue
• Clinical manifestations almost same
• Co-occurrence recently in Maharashtra
65.
66. Virus Isolation
• Most definitive
• Sample – 2-5 ml Whole blood
• Time – 1st wk of illness
• Collection – Heparinized tube
• Transport – In Ice
• CHIK virus – Cytopathic effects in cell line – BHK-
21,HeLa & Vero Cells.
• Confirmed – CHIK specific Antiserum
• Results – 1-2 wks
• BSL-3 Labs – Reduces risk of viral transmission
67. RT - PCR
• Primer pairs amplifying specific components of 3
structural gene regions
- Capsid ( C )
- Envelope E2
- Part of Envelope E1
Results – 1-2 days
Specimen – Heparinized whole blood
68. Serological diagnosis
• Specimen – 10-15 ml whole blood sera
• Acute phase serum - Immediately
• Convalescent phase serum – 10-14 days after disease
onset
• Transported – At 4 degrees & not frozen
[immediately]
- If sera – Shipped frozen
69. Serological diagnosis
• Acute phase – 4 fold increase in Ab than
Convalescent phase
• Demonstrate IgM Ab specific for CHIK virus
- MAC-ELISA [IgM Ab Capture ELISA]
- Results – 2-3 days
- Cross reactions – O’nyong-nyong & Semliki Forest
- Confirmation – Neutralization tests & HIA
70.
71.
72. Box 1: Existing Laboratory Network for Diagnosing Chikungunya
Country Serological Test PCR
India National Institute of Virology,
Pune
National Institute of Virology,
Pune
Indonesia NIHRD, NAMRU-2, NIHRD ,NAMRU-2
Myanmar Department of Medical
Research
NA
Sri Lanka Medical Research Institute Medical Research Institute
Thailand NIH, Bangkok, AFRIMS NIH, Bangkok, AFRIMS
73.
74. Treatment, Prevention & Control
• Treatment
- Not life threatening
- Symptomatic – Pain & Fever
- Rest
- Convalescence – 1 yr or more
- Persistent joint pain – Analgesic
- Long-term anti-inflammatory therapy
75. Prevention & Control
• No vaccine
• Prevention – Avoid Mosquito bites & Elimination of
breeding sites
76. Avoid Mosquito bites
• Full sleeve clothes & long dresses
• Mosquito coils, Repellents & Vapour mats
• Mosquito Nets – Babies, Old people.
• Nets & Curtains Treated with Permethrin
77. Prevent Mosquito breeding
• Manmade containers – Discarded tires,Flower
pots,oldoil drums,animal water troughs,water
storage vessels,plastic food containers
• Eliminated by
- Draining from coolers,tanks,barrels,drums & buckets
- Emptying coolers when not in use
- Cooperating with public health authorities
78. Role of Public health authorities
• National programme – Strengthened & Efficiently
implemented
• Legislations – Enforced
• Communities – Active cooperation
79. Epidemiological determinants
• Agent
- Group B Toga virus- KFD
virus
• Natural host & reservoir
- Rats, Squirrels, Birds &
Bats
- Monkeys- Amplifying host
- Cattle- Maintain tick
population
- Human- Incidental or
dead end host
81
Vector
-Hard ticks
-Soft ticks
Host factors
-Age, Sex, Occupation,
Human activity
Transmission
- Monkey- Tick- Man
Incubation period
- 3 to 8 days
80. Clinical features
• Acute phase; 2 weeks
sudden fever,head ache & myalgia
• Second phase
meningoencephalitis,tremors, mental defects
• Severe cases
GI haemorrhages
DIAGNOSIS
Virus isolation from blood and serology.
82
81. Control
• Ticks; carbaryl fenthion spray
2.24 kgs per hectare
• Hot spot- 50 metres around monkey death
• Restrict cattle movement in forests
• Vaccination; killed KFD vaccine
• Personal protection; repellants.
83
82. Be aware of peak mosquito hours
o For many mosquitoes, peak hours are between dusk
and dawn or evening and early morning.
o For the mosquitoes that transmits La Crosse
encephalitis virus peak hours are actually during the
daytime (dawn until dusk).
Use insect repellant that contains DEET, picaridin,
IR3535 or oil of lemon eucalyptus on exposed skin
and clothing when outdoors.
o Always follow package directions.
o Apply sparingly to children, avoiding hands and face,
and wash them with soap and water when they
come indoors.
o Permethrin is a repellant that can be applied to
clothing and provide protection through multiple
washes. Do not apply permethrin-containing
repellants directly to skin.
Wear protective clothing such as long sleeves,
pants, and socks when weather permits
Install and repair window screens as needed to
keep mosquitoes out of homes
Mosquitoes can lay eggs in small amounts of
water. Remove breeding sites around the
home:
o Empty standing water from flower pots, buckets,
barrels, and tires
o Change the water in pet dishes regularly
o Replace water in bird baths weekly
o Drill holes in tire swings so the water drains out
o Empty children’s wading pools and store on their
side when not in use
o Empty standing water from canoes and boats
84
86. Nat Vector Borne Disease Control Program
Objective of controlling malaria, kala azar, filaria, J.E,
dengue fever and dengue hemorrhagic fever.
Strategies for NVBDCP
1. Early diagnosis and prompt treatment
2. Integrated vector control
3. Epidemic preparedness and rapid response
4. Behavior change communication
5. Intersectoral coordination
6. Human resource development
7. Monitoring and evaluation.
88